title: Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan.
abstract: In addition to headache, migraine is characterized by a series of symptoms that negatively affects the quality of life of patients. Generally, these are represented by nausea, vomiting, photophobia, phonophobia and osmophobia, with a cumulative percentage of the onset in about 90% of the patients. From this point of view, menstrually related migraine--a particularly difficult-to-treat form of primary headache--is no different from other forms of migraine. Symptomatic treatment should therefore be evaluated not only in terms of headache relief, but also by considering its effect on these migraine-associated symptoms (MAS). Starting from the data collected in a recently completed multicentre, randomized, double-blind, placebo-controlled, cross-over study with almotriptan in menstrually related migraine, an analysis of the effect of this drug on the evolution of MAS was performed. Data suggest that almotriptan shows excellent efficacy on MAS in comparison to the placebo, with a significant reduction in the percentages of suffering patients over a 2-h period of time.
authors.affiliation: Department of Gynecology and Obstetrics, Women's Headache Center, University of Turin, Via Ventimiglia 3, 10126, Turin, Italy. gb.allais@tiscali.it
authors.forename: Gianni
authors.initials: G
authors.lastname: Allais
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Acuto
authors.forename: Chiara
authors.initials: C
authors.lastname: Benedetto
authors.forename: Giovanni
authors.initials: G
authors.lastname: D'Andrea
authors.forename: Licia
authors.initials: L
authors.lastname: Grazzi
authors.forename: Gian Camillo
authors.initials: GC
authors.lastname: Manzoni
authors.forename: Franca
authors.initials: F
authors.lastname: Moschiano
authors.forename: Florindo
authors.initials: F
authors.lastname: d'Onofrio
authors.forename: Fabio
authors.initials: F
authors.lastname: Valguarnera
authors.forename: Gennaro
authors.initials: G
authors.lastname: Bussone
mesh_terms: D000328:Adult; D018592:Cross-Over Studies; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D020326:Migraine without Aura / Q000150:complications* / Q000188:drug therapy; D009325:Nausea / Q000188:drug therapy; D010147:Pain Measurement; D020795:Photophobia / Q000188:drug therapy; D011293:Premenstrual Syndrome / Q000150:complications* / Q000188:drug therapy; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D016896:Treatment Outcome; D014363:Tryptamines / Q000627:therapeutic use*; D014839:Vomiting / Q000188:drug therapy
chemical_list: D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C409045:almotriptan
references.citation: Cephalalgia. 2002 Jul;22(6):453-61
references.pmid: 12133045
references.citation: Neurol Sci. 2006 May;27 Suppl 2:S193-7
references.pmid: 16688629
references.citation: Headache. 2008 Feb;48(2):248-58
references.pmid: 18234046
references.citation: Expert Rev Neurother. 2007 Sep;7(9):1105-20
references.pmid: 17868010
references.citation: Cephalalgia. 2004 Sep;24(9):707-16
references.pmid: 15315526